$3.38
-0.20-5.59%
Last update: Nov 10, 4:00 PM
Upstream Bio Inc
UPBNASDAQ
Upstream Bio fell 84.8% from $23.50 to $3.58, behind the S&P 500's +10.0%. Its worst day was Feb 11 (−47.2%), and its low came Oct 23 at $2.74.
Nov 10, 2025 – Nov 9, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
Upstream Bio closed at its highest level of the year, 38.7% above where the year started.
+3.0% · S&P 500 −0.2%
Story events cover the past 12 months · Times ET
Verekitug provided statistically significant and clinically meaningful reductions in annualized asthma exacerbation rate (AAER) with 100 mg q12 and 400 mg q24 week dosing.Verekitug also delivered clinically meaningful
−47.2%, the year's worst day, on 9M shares, the year's heaviest volume · S&P 500 0.0%
Upstream Bio shares rose 15.3%, while the S&P 500 fell 0.1%.
+15.3%, the year's best day · S&P 500 −0.1%
EPS of $-0.78 missed the $-0.71 estimate on $668,000.00 revenue (est. $600,942.00).
+3.4% · S&P 500 −1.8%
EPS of $-0.75 beat the $-0.76 estimate on $1.0M revenue (est. $379,736.00).
+4.6% · S&P 500 +0.6%
EPS of $-0.73 beat the $-0.76 estimate on $773,000.00 revenue (est. $435,800.00).
−4.7% · S&P 500 −0.3%
Upstream Bio shares fell 14.9%, while the S&P 500 fell 0.0%.
−14.9% · S&P 500 0.0%
Upstream Bio closed at its lowest level of the year, 88.3% below where the year started.
−8.4% · S&P 500 −0.5%
Where it ended: a close of $3.58 on Nov 9, 2026. Up next: Q3 2026 earnings on Nov 10, 2026 (EPS est. $-0.72, revenue est. $540,232.00).
Nothing in the past 12 months.
All UPB dividend historyReplay the year: the line draws itself and stops at each of the 8 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for UPB and SPY from Benzinga historical bars. Not investment advice.
